Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 20/20 | 0.58 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22565992 | 1.00 | AR (0.58) | ARCRBN | |
| SCHEMBL22565148 | 0.89 | AR (0.60) | AR | |
| SCHEMBL31565398 | 0.89 | AR (0.55) | AR | |
| SCHEMBL25315777 | 0.88 | AR (0.72) | ARCRBN | |
| SCHEMBL22565314 | 0.88 | AR (0.72) | ARCRBN | |
| SCHEMBL22565145 | 0.84 | AR (0.62) | AR | |
| SCHEMBL22565160 | 0.82 | AR (0.59) | AR | |
| SCHEMBL27014832 | 0.81 | AR (0.72) | ARCRBN | |
| SCHEMBL22566100 | 0.81 | AR (0.59) | AR | |
| SCHEMBL17941080 | 0.80 | AR (0.73) | ARCRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230091225-A1 | Bifunctional chimeric heterocyclic compounds for targeted degradation of androgen receptors and use thereof | HINOVA PHARMACEUTICALS INC. (CN) | 2023-03-23 | — | — | US | disclosed |
| EP-3957633-A1 | A CLASS OF BIFUNCTIONAL CHIMERIC HETEROCYCLIC COMPOUNDS FOR TARGETED DEGRADATION OF ANDROGEN RECEPTORS AND USE THEREOF | Hinova Pharmaceuticals Inc. (CN) | 2022-02-23 | — | — | EP | disclosed |
| CN-111825657-A | Dual-function chimeric heterocyclic compound for targeted degradation of androgen receptor and application thereof | 成都海创药业有限公司 | 2020-10-27 | — | — | CN | disclosed |
| WO-2020211822-A1 | A CLASS OF BIFUNCTIONAL CHIMERIC HETEROCYCLIC COMPOUNDS FOR TARGETED DEGRADATION OF ANDROGEN RECEPTORS AND USE THEREOF | 成都海创药业有限公司 | 2020-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230091225-A1 | Bifunctional chimeric heterocyclic compounds for targeted degradation of androgen receptors and use thereof | AR, ADRM1, PSMA1 | AR 1/4885CRBN 618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.